BioSpace News Archive

Immunocore announces that United Kingdom’s Medicines and Healthcare products Regulatory Agency has accepted a Market Authorisation Application seeking the approval of tebentafusp for the treatment of patients with metastatic uveal melanoma.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Mel Hayes as Chief Commercial Officer, effective September 7, 2021.

Longboard Pharmaceuticals, Inc. announced that the Company successfully completed the multiple ascending dose portion of a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of LP352, an oral, centrally acting, next-generation 5-HT2c receptor superagonist, in healthy volunteers.

Intelivation Technologies, a medical device company with a growing product portfolio announced that they have achieved FDA 510 Clearance of the Advantage-C™ PEEK Cervical Interbody Fusion device.

Mission Bio today announced two key improvements to the core capabilities of its Tapestri Platform intended to expand its accessibility and utility in the area of hematologic oncology (heme-onc) research.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced it is formally beginning the process towards an Investigational New Drug application filing with the Food and Drug Administration with its DehydraTECH-processed cannabidiol as a prospective registered pharmaceutical treatment for hypertension.

VectivBio Holding AG today announced the appointment of Scott Applebaum as Chief Legal Officer & Corporate Secretary.

Antibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15.

Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2021 on Wednesday, October 27, 2021. During a conference call at 8 a.m. ET on October 27, 2021, company executives will review financial results and address inquiries from investors and analysts.

Science 37 and Foundation Medicine today announced a collaboration to enable decentralized clinical research in oncology that will optimize recruitment and enrollment, improve patient retention, and expand access to precision cancer care.